These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1022 related articles for article (PubMed ID: 24954535)

  • 41. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Atypical KRAS
    Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
    Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
    Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
    Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
    [TBL] [Abstract][Full Text] [Related]  

  • 46. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
    Tu B; Yao J; Ferri-Borgogno S; Zhao J; Chen S; Wang Q; Yan L; Zhou X; Zhu C; Bang S; Chang Q; Bristow CA; Kang Y; Zheng H; Wang H; Fleming JB; Kim M; Heffernan TP; Draetta GF; Pan D; Maitra A; Yao W; Gupta S; Ying H
    JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31557131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GNAS
    Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
    Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation.
    Ma J; Gong F; Kim E; Du JX; Leung C; Song Q; Logsdon CD; Luo Y; Li X; Lu W
    Cancer Lett; 2024 Apr; 586():216694. PubMed ID: 38307409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis.
    Costamagna A; Natalini D; Camacho Leal MDP; Simoni M; Gozzelino L; Cappello P; Novelli F; Ambrogio C; Defilippi P; Turco E; Giovannetti E; Hirsch E; Cabodi S; Martini M
    Gastroenterology; 2022 Apr; 162(4):1242-1255.e11. PubMed ID: 34922945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice.
    Young CC; Baker RM; Howlett CJ; Hryciw T; Herman JE; Higgs D; Gibbons R; Crawford H; Brown A; Pin CL
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):93-113. PubMed ID: 30510993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
    Ijichi H; Chytil A; Gorska AE; Aakre ME; Fujitani Y; Fujitani S; Wright CV; Moses HL
    Genes Dev; 2006 Nov; 20(22):3147-60. PubMed ID: 17114585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.
    Han J; Xu J; Liu Y; Liang S; LaBella KA; Chakravarti D; Spring DJ; Xia Y; DePinho RA
    Genes Dev; 2023 Sep; 37(17-18):818-828. PubMed ID: 37775182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
    Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
    Fujimura K; Wang H; Watson F; Klemke RL
    Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions.
    Gout J; Pommier RM; Vincent DF; Ripoche D; Goddard-Léon S; Colombe A; Treilleux I; Valcourt U; Tomasini R; Dufresne M; Bertolino P; Bartholin L
    Pancreatology; 2013; 13(3):191-5. PubMed ID: 23719586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.
    Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E
    Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.
    Lubeseder-Martellato C; Alexandrow K; Hidalgo-Sastre A; Heid I; Boos SL; Briel T; Schmid RM; Siveke JT
    EBioMedicine; 2017 Feb; 15():90-99. PubMed ID: 28057438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.
    Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA
    Cancer Discov; 2011 Jul; 1(2):158-69. PubMed ID: 21984975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
    Zhao WG; Yu SN; Lu ZH; Ma YH; Gu YM; Chen J
    Carcinogenesis; 2010 Oct; 31(10):1726-33. PubMed ID: 20675343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.